Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangart has reported that an independent data safety monitoring board has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan, under current protocols.
Subscribe to our email newsletter
This recommendation follows the data safety monitoring board’s (DSMB) review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe. The DSMB will conduct another review afte r two- thirds of the patients have been enrolled.
Hemospan is a hemoglobin-based oxygen transport agent designed to serve as oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.